LDL cholesterol: what the test measures, normal and optimal levels, and what a high LDL means

Cholesterol does not travel loose in the blood; it is packaged into lipoprotein particles, and LDL cholesterol (LDL-C) is the amount of cholesterol carried inside low-density lipoprotein particles. These are the particles that cross into the artery wall, are taken up by immune cells and accumulate as plaque over decades. The LDL value on a lipid panel is therefore a measure of how much of this plaque-forming cargo is circulating.

On most routine panels LDL is not measured directly but calculated: total cholesterol minus HDL cholesterol minus an estimate of the cholesterol in triglyceride-rich particles. The classic Friedewald formula divides triglycerides by five for that estimate and becomes unreliable when triglycerides are above about 400; many laboratories now use the Martin-Hopkins or Sampson equations, which stay accurate at higher triglycerides and lower LDL values. A direct LDL assay exists for the cases the equations cannot handle.

LDL-C is a concentration of cholesterol, not a count of particles. Two people with the same LDL-C can carry very different numbers of LDL particles if their particles differ in size, which is why apolipoprotein B — one molecule per particle — and LDL particle number are used alongside LDL-C when the two disagree, most often in people with high triglycerides, diabetes or metabolic syndrome.

Cholesterol screening is recommended for all adults, with a first lipid panel in the twenties and repeat testing every four to six years in people at low risk and more often as risk rises. Anyone with high blood pressure, diabetes, a family history of early heart disease, smoking, obesity or kidney disease is tested more frequently, and anyone on cholesterol-lowering treatment is retested four to twelve weeks after a change and then every three to twelve months.

Children are screened once between ages 9 and 11 and again between 17 and 21, earlier when a parent has very high cholesterol or early heart disease, because familial hypercholesterolemia — an inherited LDL receptor defect affecting roughly one in 250 people — produces LDL levels above 190 from childhood and is far easier to treat before plaque forms.

People who eat very low-carbohydrate or ketogenic diets, who have recently gained or lost significant weight, who are pregnant or have an underactive thyroid also benefit from a panel, because each of these can move LDL substantially in either direction.

LDL comes on every lipid panel, with total cholesterol, HDL and triglycerides, which a doctor can order or you can order online through TestWell for a draw at a Quest or Labcorp patient service center; a licensed physician reviews the order and results post to your portal within one to three business days with each value against its band. An advanced lipid panel adds ApoB, Lp(a) and particle measures for people whose standard panel does not explain their risk.

Fasting for nine to twelve hours was the rule for decades because triglycerides rise after meals and distort the calculated LDL. Current guidelines accept a non-fasting panel for screening, since LDL-C itself changes little after eating, but a fasting draw is still preferred when triglycerides are high, when LDL is borderline, or when the result will decide treatment. Water, black coffee and usual medications are fine.

Hold off on the test during or just after an acute illness, surgery or heart attack, which lower LDL for several weeks, and mention recent diet changes, alcohol use, pregnancy, thyroid problems and any steroid, retinoid or hormone treatment to the ordering physician, since all of them shift the result.

The familiar US categories, from the National Cholesterol Education Program and carried into current guidelines, are: optimal under 100 milligrams per deciliter; near optimal 100 to 129; borderline high 130 to 159; high 160 to 189; very high 190 and above. Laboratories often print the whole scale rather than a single reference range, and a value above 190 at any age raises the question of familial hypercholesterolemia regardless of other risk factors.

These bands describe the general population, not the target for an individual. Guidelines set treatment goals by overall risk: people with established heart or vascular disease are generally treated to below 70, and below 55 after repeated events; people with diabetes or an estimated ten-year risk above 20 percent toward below 70; and lower-risk adults are advised on lifestyle unless LDL is persistently 190 or more. The ten-year risk calculator, which combines age, blood pressure, cholesterol, diabetes and smoking, decides which goal applies.

There is no established lower limit of concern. Very low LDL from medication, down into the 20s and 30s, has not shown harm in the large trials of intensive therapy, and some people have lifelong LDL in that range from genetic variants with no ill effect.

Diet high in saturated and trans fats, excess body weight (especially around the waist), and physical inactivity are the common contributors, and each moves LDL by a modest but real amount. Genetics set the baseline: polygenic variation explains most of the difference between people eating the same diet, and familial hypercholesterolemia produces very high levels from birth. LDL also rises with age and, in women, after menopause.

Secondary causes are worth excluding before treatment, because fixing them fixes the LDL: an underactive thyroid, nephrotic syndrome and other kidney disease, cholestatic liver disease, poorly controlled diabetes, pregnancy, anorexia nervosa, and medications including some diuretics, older beta-blockers, corticosteroids, anabolic steroids, progestins, retinoids and certain antiretroviral and immunosuppressive drugs. Very low-carbohydrate diets raise LDL markedly in a minority of people, sometimes above 200.

A high LDL has no symptoms. Plaque builds silently for decades; the first sign is often chest pain, a heart attack or a stroke, which is the reason screening starts young and treatment decisions rest on the number and the risk calculation rather than on how someone feels. Yellowish deposits around the eyelids or on tendons (xanthelasma, xanthomas) and a gray-white ring around the cornea before age 45 suggest a long-standing, usually inherited, elevation.

A low LDL is almost always good news or a treatment effect. Statins, ezetimibe and PCSK9 inhibitors lower LDL by 30 to 70 percent, and a low value in someone on these drugs means they are working. Lifelong low LDL from inherited variants in PCSK9 or APOB is associated with markedly lower rates of heart disease and no recognized harm.

LDL that falls without explanation, or very low LDL in someone not on treatment, occasionally reflects another condition: an overactive thyroid, malabsorption or malnutrition, advanced liver disease (the liver makes the lipoproteins), chronic inflammation or infection, some cancers, or rare genetic disorders of lipoprotein production. Acute illness, surgery and heart attack lower LDL temporarily for weeks, which is why panels drawn in hospital are repeated later.

LDL-C remains the primary target in guidelines, but three companions refine it. Non-HDL cholesterol (total minus HDL) captures the cholesterol in all plaque-forming particles, including the triglyceride-rich ones LDL-C misses, needs no fasting and is now a co-target; it typically runs about 30 above the LDL goal. Apolipoprotein B counts the particles themselves and is the better guide when triglycerides are high or LDL-C is discordant with risk. Lipoprotein(a) is a genetically set, mostly diet-resistant particle that adds independent risk and is measured once in a lifetime for most people.

For most adults a standard lipid panel is the right first test and LDL-C the right first number. An advanced panel earns its place when LDL-C is near a decision threshold, when triglycerides are above 150 or there is diabetes or metabolic syndrome, when heart disease has occurred despite a normal LDL, or when a strong family history is unexplained — the situations in which ApoB or Lp(a) changes what is done.